ASCO Cancer Center Booth, Abstracts

We hope you’ll visit the University of Illinois Cancer Center in Booth #10023 if you’re attending the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The Cancer Center will be a first-time exhibitor at this meeting, which regularly draws more than 40,000 attendees from around the world.

The McCormick Place South Exhibit Hall A is open June 1 through June 3 from 9 a.m. to 5 p.m.

At our booth, ASCO attendees can explore Cancer Center clinical trial flowcharts, watch a video to learn more about us,and mingle with our Cancer Center members, many of whom treat patients with cancer at UI Health, the academic health system of the University of Illinois Chicago (UIC).

Cancer Center Research at ASCO

In addition, research by Cancer Center members, trainees and co-authors will be featured at ASCO. Abstract details are below:

Real-world PET PSMA imaging patterns in a Chicago safety-net hospital

Joshua Pothen, Aseem ., Ruben Sauer Calvo, Alex Krule, Shaeker Chandran, Valerie Chuy, Salimah Mohamed, Karine Tawagi, Natalie Reizine

Breast Cancer Index re-stratifies 21-gene assay risk groups for late distant recurrence and extended endocrine therapy benefit: Results from the BCI Registry Study

Valerie Chuy, Natalia Siuliukina, Brandon O’Neal, Amanda Anderson, Kent Hoskins, Yi Zhang, Kai Treuner, VK Gadi

Real-world comparative effectiveness and cardiovascular safety of enzalutamide versus abiraterone amongst older men diagnosed with metastatic castration-resistant prostate cancer

Charles Gaber, Ebere Okpara, Abdullah Abdelaziz, Jyotirmoy Sarker, Kent Hanson, Lubna Hassan, Fang-Ju Lin, Todd Lee, Natalie Reizine

The role of shared decision-making in cancer pain management: Insights from a systematic review

Andrea Monteiro, Andro Yousef, Karen Sweiss, Robert DiDomenico, Lisa Sharp

Improving lung cancer health equity by applying deep learning to low dose CT screening of minority and disadvantaged patients

Abdul Zakkar, Alexander Krule, Mehak Miglani, VK Gadi, Kevin Kovitz, Mary Pasquinelli, Frank Weinberg, Yamile Molina, Sage Kim, Aly Khan, Ryan Nguyen, Ameen Salahudeen

Abemaciclib dose escalation to maintain intensity (ADE-MI)

Kevin Prescott, VK Gadi, Oana Danciu, Kent Hoskins, Abiola Ibraheem, Jovonne Owens, Zhengjia Chen

Examining knowledge of cancer-related family history in an urban underserved patient population

Monet Jones, Daniel Ludi, Irann Martinez, Keith Naylor

Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer

Abiola Ibraheem, VK Gadi, Kent Hoskins, Amina Chaudhry

Characterization of DNA damage repair mutations in lung cancer in an underserved urban patient population

Jeremy Kao, Mary Pasquinelli, Ryan Nguyen, Lawrence Feldman, Frank Weinberg

Characterization of DNA damage repair (DDR) alterations and the tumor immune microenvironment (TIME) in advanced non-small cell lung cancer (NSCLC)

Kamya Sankar, Jacob Mercer, Ellen Jaeger, Jen Godden, Jonathan Berkman, Edward Williams, Michael Thompson, Shetal Patel, Karen Reckamp, Frank Weinberg

Enhancing diverse representation in clinical studies: Recommendations from external subject matter experts (SMEs) and patients to optimize protocols, informed consent and study designs

Gregory Vidal, Haiying Cheng, Andrea Curry, Oana Danciu, Balazs Halmos, Jennifer Hopton-Jones, Stephen Huddleston, Kapil Kapoor, Maya Khalil, Ryan Nguyen, Jennifer Messner, Jason Porter, Brieyona Reaves, Meredith Russell, Suyasha Gupta, Lauren Henderson, Meghan Mckenzie, Diana Ndunda, Noah Rosenberg, Ruma Bhagat

Risk of VTE in TNBC treated with neoadjuvant immunotherapy

Ayesha Farooqui, Jeremy Kao, Marwah Farooqui, Oana Danciu

Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation

Andrew Hantel, Yating Wang, Ivy Abraham, Anand Patel, Sarah Monick, Garth Rauscher, Ana Maria Avila Rodriguez, Carlos Galvez, Peter Doukas, Jessica Altman, Madelyn Burkart, Amani Erra, Maryam Zia, Melissa Larson, Ami Dave, Stephanie Tsai, Ahmed Aleem, Nepheli Raptis, Irum Khan, Gregory Abel

Investigating disparities in enrollment of patients in lung cancer clinical trials that led to FDA approval for immunotherapies between 2015 and 2023: A comparison with the US population

Nhu Le, Ryan Nguyen

Educational intervention to facilitate clinician-patient discussions of lung cancer biomarker testing at safety net and non-safety net centers

Julia Trosman, Nikki Martin, Mary Pasquinelli, Frank Weinberg, Thomas Lycan, Ruth Sacks, Jennifer Woodyard, Kevin Prescott, Paramjeet Khosla, Ashley Lile, Latha Shivakumar, Malona Fish-Steagall, Marin Sorgi, Arliene Ravelo, Christine Weldon

Prognostic utility of YBX1-mediated genes in clear cell renal cell carcinoma outcomes

Waleed Ali, Karine Tawagi, Andre Balla

A multicenter analysis evaluating educational resources utilized by hematology/oncology fellows (HOF)

Ronak Mistry, Inas Abuali, Karine Tawagi, Daniel Hausrath, Samantha Armstrong, Victoria Chung, Madeline Fitzpatrick, Kyle Kidwell, Ankoor Biswas, Fadi Taza, Maya Abdallah, Moriah Forster, Ahmad Nassar, Shivang Danak, Vivek Patel

Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer

Erin Cobain, Lajos Pusztai, Cathy Graham, Pat Whitworth, Peter Beitsch, Cynthia Osborne, Rakhshanda Layeequr Rahman, Nathalie Johnson, Adam Brufsky, Reshma Mahtani, VK Gadi, Kent Hoskins, Hannah Linden, Rita Mukhtar, Laura Esserman, Josien Haan, Katie Quinn, Andrea Menicucci, M. Audeh, Joyce O’Shaughnessy

Utility of a collaborative hematology oncology (HO) podcast series for post-ASCO updates and teaching critical appraisal

Megan Connor, Samantha Armstrong, Karine Tawagi, Ronak Mistry, Daniel Hausrath, Agrima Mian, Ankoor Biswas, Maria Khan, Madeline Fitzpatrick, Zachary Wills, Sean Taasan, Srijan Valasapalli, Vivek Patel

A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study

Alexander Pearson, Tanguy Seiwert, Roger Cohen, Nabil Saba, John Kaczmar, Mary Fidler, James Wade, Enrico Castellucci, Theodore Karrison, Rohan Katipally, Aditya Juloori, Ari Rosenberg, Daniel Haraf, Nishant Agrawal, Everett Vokes

Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group

Leonora Slatnick, Navin Pinto, Arlene Naranjo, Jed Nuchtern, Edward Attiyeh, Rochelle Bagatell, Clare Twist, Meredith Irwin, Steven DuBois, John Maris, Mary Schmidt, Araz Marachelian, Michael Armstrong, Peter Zage, Christopher Weldon, Julie Park, Holly Meany

A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153

Greg Durm, Muhammad Furqan, Richard Hall, Alberto Chiappori, Patrick Ma, Lawrence Feldman, Amit Kulkarni, Missak Haigentz, Apar Kishor Ganti, Dwight Owen, Rachel Sanborn, Nasser Hanna

Evaluation of the study of control arms in randomized clinical trials of cancer

Sandeep Jain, Marjorie Zauderer, Tarsheen Sethi, Martin Schoen, Sam Rubinstein, Ryan Nguyen, Seema Nagpal, Sanjay Mohan, Sathwik Madireddy, Mark Lythgoe, Wayne Liang, Amit Kulkarni, Shalin Kothari, Talal Hilal, Matthew Hadfield, Gaurav Goyal, Teja Ganta, Bhagirathbhai Dholaria, Alaina Brown, Jeremy Warner

A multicenter analysis of didactic curricula in a hematology oncology fellowship program

Ronak Mistry, Karine Tawagi, Inas Abuali, Samantha Armstrong, Daniel Hausrath, Sheila DeYoung, Kayla Miranda, Lauren Mendelson, Srijan Valasapalli, Dillon Cockrell, Matthew Bloom, Jessica Stempel, Megan Melody, Jonathan Berry, Vivek Patel

Integration of a focused podcast curriculum (PC) to improve hematology oncology fellow (HOF) knowledge: A multi-center cluster randomized controlled trial

Vivek Patel, Karine Tawagi, Samantha Armstrong, Daniel Hausrath, Inas Abuali, Sean Taasan, Agrima Mian, Nathaniel Wilson, Daniel Egert, Ericson Stoen, Aleena Itani, Giuliana Berardi, Yurhee Lee, Pranali Pachika, Ronak Mistry

Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)

John Stewart, Melissa Lowe, Andrew Chapple, Donna Niedzwiecki, Ashley Moyer, Emily Bolch, Shannon MacLaughlan, Edward Levine, Omeed Moaven, Niharika Nettu, John Strickler, Dan Blazer

Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data

Gregory Calip, Yookyung Christy Choi, Mona Cai, Alexander Liede, Natalie Monegro, Annie McNeill

Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas

Don Dizon, Cara Mathews, Shannon David, Jason Machan, Matthew Hadfield, Eric Marks, Rani Bansal, Christine McGinn, Faith Hassinger, Denise Luppe, Janine Grigelevich, Kelly Mitchell, Adam Braga, Ashlee Sturtevant, Roxanne Wood, Ursula Matulonis, Alexi Wright, Susana Campos, Michael Birrer

Diagnosis disclosure patterns among patients with plasma cell disorders

Maria Malik, Akshay Dalvi, Andriy Derkach, Ana Sahagun Sanchez Aldana, Jorge Arturo Hurtado Martínez, Gia Merlo, Jennifer Ahlstrom, Jay Hydren, Saad Usmani, Susan Chimonas, Robin Ortiz, Urvi Shah

Translate »